<DOC>
	<DOCNO>NCT00021450</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Bicalutamide goserelin may fight prostate cancer reduce production testosterone . It yet know radiation therapy effective without bicalutamide goserelin treat prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy without bicalutamide goserelin treat patient localized prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy With Without Bicalutamide Goserelin Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare potential beneficial impact radiotherapy without adjuvant bicalutamide goserelin long-term outcome patient localized prostate cancer . - Compare acute late radiation-induced side effect regimens patient . - Compare biochemical/clinical disease-free survival , overall survival , time local progression patient treat regimen . - Compare time clinical biological failure death patient treat regimen . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord tumor class ( T1b-c v T2a ) , initial prostate-specific antigen level ( 10 ng/mL vs 10-20 ng/mL v great 20 ng/mL ) , Gleason score ( 2-6 v 7-10 ) participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo 3-dimensional conformal radiotherapy intensity-modulated radiotherapy daily 5 day week 7-7.5 week . - Arm II : Patients receive adjuvant oral bicalutamide daily day 1-30 goserelin subcutaneously day 8 98 . Beginning day 8 , patient undergo radiotherapy arm I . Quality life assess baseline month 6 , 12 , 24 , 36 . Patients follow every 6 month 5 year annually thereafter . PROJECTED ACCRUAL : A total 800 patient ( 400 per treatment arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage II prostate cancer T1bc , N0 , M0 prostatespecific antigen ( PSA ) least 10 ng/mL and/or Gleason score least 7 ( UICC 1997 classification ) OR T2a , N0 , M0 ( UICC 1997 classification ) Serum PSA great 50 ng/mL No involvement pelvic lymph node PATIENT CHARACTERISTICS : Age : 80 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No malignancy within past 5 year except adequately treat basal cell skin cancer No psychological , familial , sociological , geographical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : No prior hormonal therapy Radiotherapy : No prior pelvic radiotherapy Surgery : No prior radical prostatectomy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>